NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of time. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers. While evolving DPI technology and combination therapeutic products continue to have a significant impact on the treatment of upper respiratory diseases and conditions, dry powder inhalers are making strides in applications requiring the systemic delivery of both small and large molecule and engineered macromolecules for the treatment of a range of pathologies.
• Analyzes and evaluates Dry Powder Inhalers and competing inhaled drug delivery technologies and assesses the market potential for existing and probable futur